Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells.
Psoralens are widely used for the treatment of hyperproliferative skin disease. In this work, we prepared nanoparticles (NP) containing a benzopsoralen (3-ethoxy carbonyl-2H-benzofuro[3,2-f]-1-benzopiran-2-one) by the solvent evaporation technique. We evaluated important NP parameters such as particle size, drug encapsulation efficiency, effect of the encapsulation process over the drug's photochemistry, zeta potential, external morphology, and in vitro release behavior. We also investigated the nanoparticle as a drug delivery system (DDS), as well as its target delivery to the action site, which is a very important parameter to increase the therapeutic use of psoralens and to reduce their side effects. The uptake of benzopsoralen-loaded PLGA nanoparticles by different kinds of cells found in rat peritoneal exudates was also studied. The photodamage promoted by irradiation with UV light revealed morphological characteristics of cell damage such as cytoplasmic vesiculation, mitochondrial damage, and swelling of both the granular endoplasmatic reticulum and nuclear membrane. This encapsulation method maintained the drug's properties and improved drug delivery to the target cell.
Gomes
A J
AJ
Laboratório de Fotoquímica, Instituto de Química, Universidade Federal de Uberlândia, P.O. Box 593, CEP 38400-089 Uberlândia, MG, Brazil. anderson@iqufu.ufu.br
Faustino
A S
AS
Lunardi
C N
CN
Lunardi
L O
LO
Machado
A E H
AE
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D003879:Dermatologic Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000528:radiation effects; D004337:Drug Carriers; D004339:Drug Compounding; D004705:Endocytosis; D011564:Furocoumarins / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000528:radiation effects; D066298:In Vitro Techniques; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D053758:Nanoparticles; D011701:PUVA Therapy; D010316:Particle Size; D017319:Photosensitizing Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000528:radiation effects; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013499:Surface Properties; D013678:Technology, Pharmaceutical / Q000379:methods; D014466:Ultraviolet Rays
D003879:Dermatologic Agents; D004337:Drug Carriers; D011564:Furocoumarins; D017319:Photosensitizing Agents; D011108:Polymers; C515719:psoralen A; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid